MAM
CLLS

Meeder Asset Management’s Cellectis CLLS Stock Holding History

Meeder Asset Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 2109
2020
Q1 		$0 Sell
1
-47
-98% -$701 ﹤0.01% 2350
2019
Q4 		$1K Buy
+48
New +$641 ﹤0.01% 2119

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Meeder Asset Management's CLLS Position: Q2 2020 in Review

Meeder Asset Management sold out of Cellectis (CLLS) in Q2 2020, closing a stake of 1 share.

Meeder Asset Management first reported a position in CLLS in Q4 2019 and held it in 2 quarters. The position peaked at $1K in Q4 2019. 79 funds tracked by Wall St. Rank hold CLLS as of Q2 2020.

  • Meeder Asset Management reported no remaining Cellectis position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1 Cellectis share in Q2 2020.
  • Meeder Asset Management first reported a position in Cellectis in Q4 2019 and held it in 2 quarters.
  • Meeder Asset Management's Cellectis position peaked at $1K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held Cellectis as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.